DAWN250117P35000
- 0.00
- 0.000.00%
Day One Biopharmaceuticals Newsroom
Day One Biopharm Is Maintained at Buy by Jones Trading
Day One Biopharmaceutical Analyst Ratings
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $34
Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
J.P. Morgan Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating
Day One Biopharmaceuticals: Strong Ojemda Launch Exceeds Expectations, Analyst Reiterates Overweight Rating
A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $28 to $40
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target
Day One Biopharm Price Target Maintained With a $33.00/Share by Needham
Day One Biopharmaceutical Analyst Ratings
Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Day One Biopharmaceutical Analyst Ratings
Needham Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Raises Target Price to $33
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Inari Medical (NARI)
TD Cowen Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
JP Morgan Maintains Overweight on Day One Biopharmaceutical, Lowers Price Target to $36
Day One Biopharmaceutical Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target
BofA Securities Upgrades Day One Biopharmaceuticals(DAWN.US) to Buy Rating, Raises Target Price to $24